<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02261441</url>
  </required_header>
  <id_info>
    <org_study_id>IBERICAN</org_study_id>
    <nct_id>NCT02261441</nct_id>
  </id_info>
  <brief_title>Cardiovascular and Renal Risk in Spain</brief_title>
  <acronym>IBERICAN</acronym>
  <official_title>Identificación de la poBlación Española de RIesgo CArdiovascular y reNal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>La Sociedad Española de Médicos de Atención Primaria</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>La Sociedad Española de Médicos de Atención Primaria</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      IBERICAN is a multicenter, longitudinal and observational population-based study of patients
      daily attended in Primary Care setting in Spain.

      This study is aimed to determine the prevalence and incidence of cardiovascular risk factors
      in adult population in Spain.

      Patients will be followed-up for a minimum period of 5 years, every 6 months or a lesser
      period when clinically required.

      It has been estimated that a total of 15,000 individuals will be included.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IBERICAN (Identificación de la poBlación Española de RIesgo CArdio Vascular y reNal) is a
      multicenter, longitudinal and observational population-based study of patients daily attended
      in Primary Care setting in Spain.

      The aims of IBERICAN are to determine the prevalence and incidence of cardiovascular risk
      factors in adult population in Spain. Moreover, the development of cardiovascular outcomes,
      and risk factors control rates will be also analyzed.

      In IBERICAN, subjects irrespective of the presence of risk factors or cardiovascular disease
      throughout Spain will be included.

      No specific recommendations will be provide to physicians about treatments. As a result,
      treatments of patients will be prescribed, modified or withdrawn according only to
      physicians´ judgment. The study has been approved by the ethic committee of Hospital Carlos
      III, Madrid on February 2013. Before inclusion, every patient will provide a written informed
      consent.

      Patients will be followed-up for a minimum period of 5 years, every 6 months or a lesser
      period when clinically required. Excepting a blood analysis in the previous 6 months before
      the inclusion, no other specific diagnostic tool or technique will be required for being
      included in the study. All blood and urine analysis or other techniques will be performed
      according to clinical practice during the follow-up.

      It has been estimated that a total of 15,000 individuals will be included.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular event</measure>
    <time_frame>5 years</time_frame>
    <description>Development of cardiovascular events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular risk factors</measure>
    <time_frame>5 years</time_frame>
    <description>Development of cardiovascular risk factors.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">15000</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Subjects irrespective of the presence of risk factors or cardiovascular disease throughout Spain will be included. This is an observational and non-interventional study</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational and noninterventional study</intervention_name>
    <description>No specific recommendations will be provide to physicians about treatments. As a result, treatments of patients will be prescribed, modified or withdrawn according only to physicians´ judgment.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects irrespective of the presence of risk factors or cardiovascular disease throughout
        Spain
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  National Health Care System user.

          -  Resident at Spain in the last 5 years.

          -  Attended by investigator in Primary Care setting.

        Exclusion Criteria:

          -  Change of regular residence to other city or country in the following 6 months.

          -  Life expectancy less than 5 years.

          -  Difficult to follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Goya, 25</name>
      <address>
        <city>Madrid</city>
        <zip>28001</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Escobar, MD, PhD</last_name>
      <email>escobar_cervantes_carlos@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Cavelaars AE, Kunst AE, Geurts JJ, Crialesi R, Grötvedt L, Helmert U, Lahelma E, Lundberg O, Matheson J, Mielck A, Mizrahi A, Mizrahi A, Rasmussen NK, Regidor E, Spuhler T, Mackenbach JP. Differences in self reported morbidity by educational level: a comparison of 11 western European countries. J Epidemiol Community Health. 1998 Apr;52(4):219-27.</citation>
    <PMID>9616407</PMID>
  </results_reference>
  <results_reference>
    <citation>Marrugat J, Elosua R, Martí H. [Epidemiology of ischaemic heart disease in Spain: estimation of the number of cases and trends from 1997 to 2005]. Rev Esp Cardiol. 2002 Apr;55(4):337-46. Spanish.</citation>
    <PMID>11975899</PMID>
  </results_reference>
  <results_reference>
    <citation>Fiol M, Cabadés A, Sala J, Marrugat J, Elosua R, Vega G, José Tormo Díaz M, Segura A, Aldasoro E, Moreno-Iribas C, Muñiz J, Hurtado de Saracho I, García J. [Variability in the in-hospital management of acute myocardial infarction in Spain. IBERICA Study (Investigación, Búsqueda Específica y Registro de Isquemia Coronaria Aguda)]. Rev Esp Cardiol. 2001 Apr;54(4):443-52. Spanish.</citation>
    <PMID>11282049</PMID>
  </results_reference>
  <results_reference>
    <citation>Marrugat J, Sanz G, Masiá R, Valle V, Molina L, Cardona M, Sala J, Serés L, Szescielinski L, Albert X, Lupón J, Alonso J. Six-month outcome in patients with myocardial infarction initially admitted to tertiary and nontertiary hospitals. RESCATE Investigators. Recursos Empleados en el Síndrome Coronario Agudo y Tiempos de Espera. J Am Coll Cardiol. 1997 Nov 1;30(5):1187-92.</citation>
    <PMID>9350913</PMID>
  </results_reference>
  <results_reference>
    <citation>Gispert Magarolas R, Barés Marcano MA, Freitas Ramírez A, Torné Farré M, Puigdefàbregas Serra A, Alberquilla A, Albert X, Luis Alfonso J, Caminal J, Fernández-Cuenca R, García F, Gervas J, Librero J, Martos C, Medrano MJ, Ruiz M. [Health system interventions assessment in Spain: an approach through the analysis of the time trends and the geographical variability of avoidable mortality between 1986 -2001]. Rev Esp Salud Publica. 2006 Mar-Apr;80(2):139-55. Spanish.</citation>
    <PMID>16719023</PMID>
  </results_reference>
  <results_reference>
    <citation>Félix-Redondo FJ, Fernández-Bergés D, Grau M, Baena-Diez JM, Mostaza JM, Vila J. Prevalence and clinical characteristics of peripheral arterial disease in the study population Hermex. Rev Esp Cardiol (Engl Ed). 2012 Aug;65(8):726-33. Epub 2012 Jun 22. English, Spanish.</citation>
    <PMID>22727799</PMID>
  </results_reference>
  <results_reference>
    <citation>Daniels SR. Prevention of atherosclerotic cardiovascular disease: what is the best approach and how early should we start? J Am Coll Cardiol. 2014 Jul 1;63(25 Pt A):2786-8. doi: 10.1016/j.jacc.2014.01.082. Epub 2014 May 7. Review.</citation>
    <PMID>24814499</PMID>
  </results_reference>
  <results_reference>
    <citation>Persic V. Obesity in the cardiovascular continuum. Curr Clin Pharmacol. 2013 May;8(2):159-63.</citation>
    <PMID>22950957</PMID>
  </results_reference>
  <results_reference>
    <citation>Burgmaier M, Heinrich C, Marx N. Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes? Diabet Med. 2013 Mar;30(3):289-99. doi: 10.1111/j.1464-5491.2012.03746.x. Review.</citation>
    <PMID>22804451</PMID>
  </results_reference>
  <results_reference>
    <citation>González-Juanatey JR, Cordero A. Benefits of delapril in hypertensive patients along the cardiovascular continuum. Expert Rev Cardiovasc Ther. 2013 Mar;11(3):271-81. doi: 10.1586/erc.12.188. Review.</citation>
    <PMID>23469905</PMID>
  </results_reference>
  <results_reference>
    <citation>Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvänne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F; European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012 Jul;33(13):1635-701. doi: 10.1093/eurheartj/ehs092. Epub 2012 May 3. Erratum in: Eur Heart J. 2012 Sep;33(17):2126.</citation>
    <PMID>22555213</PMID>
  </results_reference>
  <results_reference>
    <citation>Bastuji-Garin S, Deverly A, Moyse D, Castaigne A, Mancia G, de Leeuw PW, Ruilope LM, Rosenthal T, Chatellier G; Intervention as a Goal in Hypertension Treatment Study Group. The Framingham prediction rule is not valid in a European population of treated hypertensive patients. J Hypertens. 2002 Oct;20(10):1973-80.</citation>
    <PMID>12359975</PMID>
  </results_reference>
  <results_reference>
    <citation>Marrugat J, Subirana I, Comín E, Cabezas C, Vila J, Elosua R, Nam BH, Ramos R, Sala J, Solanas P, Cordón F, Gené-Badia J, D'Agostino RB; VERIFICA Investigators. Validity of an adaptation of the Framingham cardiovascular risk function: the VERIFICA Study. J Epidemiol Community Health. 2007 Jan;61(1):40-7. Erratum in: J Epidemiol Community Health. 2007 Jul;61(7):655.</citation>
    <PMID>17183014</PMID>
  </results_reference>
  <results_reference>
    <citation>Mazón-Ramos P. [Cardiovascular risk in the 21st century: identifying risk in primary prevention. Controlling risk in secondary prevention]. Rev Esp Cardiol (Engl Ed). 2012 Jul;65 Suppl 2:3-9. Review. Spanish.</citation>
    <PMID>22921168</PMID>
  </results_reference>
  <results_reference>
    <citation>Kavouras SA, Panagiotakos DB, Pitsavos C, Chrysohoou C, Arnaoutis G, Skoumas Y, Stefanadis C. Physical Activity and Adherence to Mediterranean Diet Increase Total Antioxidant Capacity: The ATTICA Study. Cardiol Res Pract. 2010 Oct 20;2011:248626. doi: 10.4061/2011/248626.</citation>
    <PMID>20981278</PMID>
  </results_reference>
  <results_reference>
    <citation>Panagiotakos DB, Pitsavos C, Stefanadis C. Dietary patterns: a Mediterranean diet score and its relation to clinical and biological markers of cardiovascular disease risk. Nutr Metab Cardiovasc Dis. 2006 Dec;16(8):559-68. Epub 2006 Feb 9.</citation>
    <PMID>17126772</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2014</study_first_submitted>
  <study_first_submitted_qc>October 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2014</study_first_posted>
  <last_update_submitted>April 30, 2017</last_update_submitted>
  <last_update_submitted_qc>April 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>La Sociedad Española de Médicos de Atención Primaria</investigator_affiliation>
    <investigator_full_name>Carlos Escobar</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Cardiovascular disease</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Smoking</keyword>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>Cardiovascular risk factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

